1. CHARACTERIZATIONS OF DRUG CARRYING MAGNETIC NANOPARTICLES FOR TUMOR THERAPY: BIOLOGICAL OUTCOME AND FIRST IMMUNOLOGICAL ASPECTS.
- Author
-
Dürr, S., Tietze, R., Lyer, S., Janko, C., Schreiber, E., Mann, J., Turcu, R., Gitter, K., Odenbach, S., Vasylyev, S., Herrmann, M., Peukert, W., and Alexiou, C.
- Subjects
- *
MAGNETIC properties of nanoparticles , *MAGNETIC properties of nanostructured materials , *CANCER treatment , *CANCER chemotherapy , *CANCER immunology , *TARGETED drug delivery - Abstract
Nanosized magnetic drug carriers offer a splendid prospect for directed drug application. The increased drug concentration in cancer tissue reached for this kind of application enables therapeutic effects on tumors that cannot be achieved using conventional chemotherapeutic treatment. Characterizing the drug targeting system and its behavior in vitro is necessary for understanding the biological outcome. In our studies, IRspectroscopy shows covalent binding of the bioeompatible fatty acid layer. Although binding of mitoxantrone (MTO) to particles is hardly defined, considerable amounts of drug can be carried by nanopaxticles. Furthermore, the nanosized drug carrier complex has to be investigated due to its biological outcome. Real-time cell analysis is useful to observe the therapeutic particles concerning their outcome in cell culture time-resolved up to several days. First experiments in concordance to a conventional assay show that the effectivity of nanoparticle bound MTO in cell culture is higher than treatment with pure MTO. A preliminary study demonstrates that the burden of the immune system is reduced by Magnetic Drug Targeting (MDT) vs. conventional chemotherapy. For a better understanding of MDT for cancer treatment, further studies have to be done to explain especially the binding behavior of superpaxamagnetic iron oxide nanopaxticles to the respective chemotherapeutic agent. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF